Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LQDANASDAQ:MRNSNASDAQ:QURENYSE:ZYME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLQDALiquidia$14.18-9.1%$14.74$8.26▼$19.41$1.33B0.241.08 million shs2.37 million shsMRNSMarinus Pharmaceuticals$0.55-0.2%$0.55$0.22▼$1.97$30.32M1.031.75 million shs260 shsQUREuniQure$15.04-3.0%$12.52$3.73▼$19.18$823.83M0.11.90 million shs763,487 shsZYMEZymeworks$11.23+0.1%$11.67$8.21▼$17.70$780.65M1.24600,925 shs641,238 shs10 Stocks Set to Soar in Spring 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLQDALiquidia-9.10%-14.89%-0.35%-7.68%+15.38%MRNSMarinus Pharmaceuticals0.00%0.00%0.00%0.00%-63.39%QUREuniQure-2.97%-2.97%+7.66%+24.61%+218.64%ZYMEZymeworks+0.09%-5.95%-12.81%-15.82%+28.93%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLQDALiquidia3.6128 of 5 stars4.51.00.00.03.34.20.6MRNSMarinus Pharmaceuticals2.4167 of 5 stars3.20.00.04.20.01.70.6QUREuniQure3.0271 of 5 stars4.51.00.00.02.62.50.6ZYMEZymeworks3.1985 of 5 stars4.50.00.00.02.63.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLQDALiquidia 3.00Buy$26.6788.06% UpsideMRNSMarinus Pharmaceuticals 2.40Hold$4.79771.56% UpsideQUREuniQure 2.91Moderate Buy$37.82151.45% UpsideZYMEZymeworks 2.90Moderate Buy$21.0087.00% UpsideCurrent Analyst Ratings BreakdownLatest LQDA, QURE, ZYME, and MRNS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/28/2025LQDALiquidiaScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$36.00 ➝ $37.005/28/2025LQDALiquidiaWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$20.00 ➝ $23.005/28/2025LQDALiquidiaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.005/28/2025LQDALiquidiaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$29.00 ➝ $35.005/21/2025LQDALiquidiaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.005/20/2025ZYMEZymeworksTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/20/2025ZYMEZymeworksTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/19/2025LQDALiquidiaOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetMarket Perform ➝ Underperform$13.005/19/2025QUREuniQureCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/12/2025LQDALiquidiaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.005/12/2025LQDALiquidiaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$29.00 ➝ $29.00(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLQDALiquidia$14.14M85.70N/AN/A$0.73 per share19.42MRNSMarinus Pharmaceuticals$30.99M0.98N/AN/A$0.31 per share1.77QUREuniQure$20.20M40.78N/AN/A$4.34 per share3.47ZYMEZymeworks$93.38M8.37N/AN/A$6.63 per share1.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLQDALiquidia-$78.50M-$1.58N/AN/AN/A-765.38%-163.21%-67.14%8/6/2025 (Estimated)MRNSMarinus Pharmaceuticals-$141.40M-$2.47N/AN/AN/A-446.48%-7,831.35%-120.74%8/11/2025 (Estimated)QUREuniQure-$308.48M-$4.39N/AN/AN/A-837.80%-188.82%-32.17%8/7/2025 (Estimated)ZYMEZymeworks-$118.67M-$1.49N/AN/AN/A-182.75%-23.00%-18.04%8/7/2025 (Estimated)Latest LQDA, QURE, ZYME, and MRNS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025QUREuniQure-$1.07-$0.82+$0.25-$0.82$5.93 million$1.57 million5/8/2025Q1 2025LQDALiquidia-$0.42-$0.45-$0.03-$0.45$3.23 million$3.12 million5/8/2025N/AZYMEZymeworks-$0.45-$0.30+$0.15N/A$20.65 million$27.11 million3/19/2025Q4 2024LQDALiquidia-$0.38-$0.46-$0.08-$0.46$4.60 million$2.92 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLQDALiquidiaN/AN/AN/AN/AN/AMRNSMarinus PharmaceuticalsN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/AZYMEZymeworksN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLQDALiquidiaN/A6.336.33MRNSMarinus PharmaceuticalsN/A1.661.47QUREuniQure0.926.516.51ZYMEZymeworksN/A4.104.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLQDALiquidia64.54%MRNSMarinus Pharmaceuticals98.80%QUREuniQure78.83%ZYMEZymeworks92.89%Insider OwnershipCompanyInsider OwnershipLQDALiquidia26.50%MRNSMarinus Pharmaceuticals5.46%QUREuniQure4.74%ZYMEZymeworks1.92%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLQDALiquidia5085.49 million59.16 millionOptionableMRNSMarinus Pharmaceuticals11055.22 million52.20 millionOptionableQUREuniQure50054.78 million46.43 millionOptionableZYMEZymeworks46069.58 million67.56 millionOptionableLQDA, QURE, ZYME, and MRNS HeadlinesRecent News About These CompaniesZymeworks Inc. (NYSE:ZYME) Receives Consensus Rating of "Moderate Buy" from AnalystsMay 28 at 1:31 AM | marketbeat.comZymeworks Inc. (NYSE:ZYME) Receives Average Rating of "Moderate Buy" from AnalystsMay 27 at 1:33 AM | americanbankingnews.comWhat is HC Wainwright's Forecast for Zymeworks Q2 Earnings?May 24, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Shares Acquired by Northern Trust CorpMay 23, 2025 | marketbeat.comZymeworks (NYSE:ZYME) Research Coverage Started at TD SecuritiesMay 23, 2025 | americanbankingnews.comZymeworks (NYSE:ZYME) Earns Buy Rating from Analysts at TD CowenMay 23, 2025 | americanbankingnews.comZymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical ConferencesMay 22, 2025 | globenewswire.comTD Cowen Initiates Coverage on Zymeworks (NYSE:ZYME)May 22, 2025 | marketbeat.comPoint72 Asset Management L.P. Boosts Stock Position in Zymeworks Inc. (NYSE:ZYME)May 22, 2025 | marketbeat.comZymeworks (NYSE:ZYME) Stock Price Up 4.2% After Insider Buying ActivityMay 22, 2025 | americanbankingnews.comZymeworks Inc. Presents Promising Preclinical Data for ZW1528, a Novel Bispecific Antibody Targeting IL-4Rα and IL-33 for Respiratory InflammationMay 21, 2025 | nasdaq.comZymeworks Inc. (NYSE:ZYME) Stake Lessened by Vestal Point Capital LPMay 21, 2025 | marketbeat.comTD Securities Initiates Coverage of Zymeworks (ZYME) with Buy RecommendationMay 21, 2025 | msn.comTD Cowen Initiates Zymeworks With ‘Buy’, Cites Ziihera’s ‘Blockbuster Potential’ In Biliary Tract Cancer TherapyMay 21, 2025 | msn.comZymeworks Announces Participation in Upcoming Investor ConferencesMay 21, 2025 | globenewswire.comZymeworks Inc.: Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International ConferenceMay 20, 2025 | finanznachrichten.dePolar Asset Management Partners Inc. Buys New Holdings in Zymeworks Inc. (NYSE:ZYME)May 20, 2025 | marketbeat.comZymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 5,919 SharesMay 20, 2025 | insidertrades.comZymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International ConferenceMay 19, 2025 | globenewswire.comZymeworks Inc. (NYSE:ZYME) Shares Sold by Prosight Management LPMay 17, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Has $5.21 Million Position in Zymeworks Inc. (NYSE:ZYME)May 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeLQDA, QURE, ZYME, and MRNS Company DescriptionsLiquidia NASDAQ:LQDA$14.18 -1.42 (-9.10%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$14.57 +0.39 (+2.75%) As of 05/28/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.Marinus Pharmaceuticals NASDAQ:MRNS$0.55 0.00 (-0.16%) As of 02/11/2025Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania.uniQure NASDAQ:QURE$15.04 -0.46 (-2.97%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$15.24 +0.21 (+1.36%) As of 05/28/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.Zymeworks NYSE:ZYME$11.23 +0.01 (+0.09%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$11.23 0.00 (0.00%) As of 05/28/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
